ValiRx PLC
LSE:VAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ValiRx PLC
Income from Continuing Operations
ValiRx PLC
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ValiRx PLC
LSE:VAL
|
Income from Continuing Operations
-£1.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Income from Continuing Operations
-£35.5m
|
CAGR 3-Years
5%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Income from Continuing Operations
-$287.9m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Income from Continuing Operations
£47.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Income from Continuing Operations
-£30.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
-9%
|
|
|
Niox Group PLC
LSE:NIOX
|
Income from Continuing Operations
£7m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ValiRx PLC
Glance View
ValiRx Plc is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialization and partnering. The company is headquartered in Nuneaton, Warwickshire and currently employs 10 full-time employees. The company went IPO on 2000-02-28. The firm is engaged in the development of oncology therapeutics and companion diagnostics. The company focuses on the development of treatments in cancer and women’s health. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. Its VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer. Its VAL301 for the treatment of women with endometriosis. Its VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. Its BC201 is a combination of the peptide ingredient of VAL201 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. The company operates through divisional companies, including ValiPharma and ValiSeek.
See Also
What is ValiRx PLC's Income from Continuing Operations?
Income from Continuing Operations
-1.9m
GBP
Based on the financial report for Jun 30, 2025, ValiRx PLC's Income from Continuing Operations amounts to -1.9m GBP.
What is ValiRx PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
5%
Over the last year, the Income from Continuing Operations growth was 9%. The average annual Income from Continuing Operations growth rates for ValiRx PLC have been 5% over the past three years , 5% over the past five years , and 5% over the past ten years .
